NCT01055847View on ClinicalTrials.gov

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

August 31, 2004

Study Completion Date

September 30, 2004

Conditions
Cystic FibrosisCFLung InfectionPseudomonas Aeruginosa
Interventions
DRUG

Aztreonam for Inhalation (AI)

Aztreonam for Inhalation

DRUG

Placebo

Saline Placebo

Trial Locations (20)

19129

Philadelphia

27514

Chapel Hill

29425

Charleston

32610

Gainsville

32806

Orlando

44106

Cleveland

45404

Dayton

53792

Madison

77030

Houston

80218

Denver

84132

Salt Lake City

90027

Los Angeles

92868

Orange

94305

Stanford

98105

Seattle

92103-8376

San Diego

02114

Boston

48109-0212

Ann Arbor

68198-5190

Omaha

43205-2696

Columbus

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

Salus Pharma, Inc.

INDUSTRY

lead

Gilead Sciences

INDUSTRY